12:09 PM EDT, 08/22/2024 (MT Newswires) -- Lexaria Bioscience ( LEXX ) said Thursday that eighth-week results from an ongoing study showed that liraglutide administered through its DehydraTECH drug delivery and processing platform is "outperforming" semaglutide in promoting weight loss in animals.

According to Lexaria, the results are "of particular interest" because semaglutide has been observed to be "more than twice as effective" as liraglutide in promoting weight loss in humans. The company cautioned against comparing the results with human weight loss studies.

Lexaria said actual weight losses or slower rates of weight gain were observed in the eight weeks of dosing in all groups that received DehydraTECH drug therapies under the study. The company also said the study continues and additional results are expected.

Shares of Lexaria were down more than 5% in recent trading.

Price: 3.12, Change: -0.17, Percent Change: -5.14